Exploratory Study of DHA in Systemic Lupus Erythematosus Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03396393 |
Recruitment Status :
Not yet recruiting
First Posted : January 11, 2018
Last Update Posted : January 23, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Systemic Lupus Erythematosus | Drug: Dihydroartemisinin tablet Drug: Placebo tablet | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients will be received DHA 40mg or DHA 80mg or DHA 120mg or placebo continuously for 24 weeks. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of Dihydroartemisinin Tablets in Patients With Systemic Lupus Erythematosus |
Estimated Study Start Date : | March 2018 |
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Dihydroartemisinin 40mg
Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
|
Drug: Dihydroartemisinin tablet
DHA tablet
Other Name: No other names |
Experimental: Dihydroartemisinin 80mg
Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
|
Drug: Dihydroartemisinin tablet
DHA tablet
Other Name: No other names |
Experimental: Dihydroartemisinin 120mg
Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
|
Drug: Dihydroartemisinin tablet
DHA tablet
Other Name: No other names |
Placebo Comparator: placebo
Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
|
Drug: Placebo tablet
Placebo tablet
Other Name: No other names |
- SRI,Response at Week 24 according to a combined response index [ Time Frame: week 24 ]The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.
- Change from baseline in SLEDAI score [ Time Frame: week 4,8,12,16,20,24 ]Change from baseline in SLEDAI score at week 4,8,12,16,20,24
- Change from baseline in PAG score [ Time Frame: week 4,8,12,16,20,24 ]Change from baseline in PAG score at week 4,8,12,16,20,24
- Number of days of daily prednisone dose Less than or equal to 7.5 mg/day [ Time Frame: Baseline, Week 24 ]Number of days of daily prednisone dose Less than or equal to 7.5 mg/day from baseline over 24 weeks
- Percent of subjects with UPRO <0.5g/24h [ Time Frame: Week 4,12,24 ]Percent of subjects with UPRO <0.5g/24h from baseline at Week 4,12,24

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology;
- Positive antinuclear antibodies (ANA);
- Activity Index (SLEDAI) score must be 6-11 points, inclusive;
- Stable dose of prednisone (<30mg/d) for at least one month ;
- Active mild to moderate SLE activity as demonstrated by British Isles Lupus Assessment Group Index (BILAG);
- Males or females between 18 and 65 years old;
- Weight of 45 kg or greater.
Key Exclusion Criteria:
- Active Severe Lupus as defined by BILAG Index Level A or two or more of Level B in any body system/organ;
- Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections;
- Presence of active central nervous system (CNS) disease requiring treatment;
- Subjects with active, severe SLE disease activity which involves the renal system;
- Substance abuse or dependence;
- History of malignant cancer within the last 5 years;
- Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion;
- Subjects received any live vaccination within the 30 days prior to Visit 2;
- Subjects received intravenous immunoglobulin (IVIg) or,plasmapheresis,or High dose prednisone or equivalent (> 100 mg/day) within 90 days prior to Visit 2;
- Subjects who have had therapy with cyclophosphamide within 180 days prior to Visit 2 .

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03396393
Contact: Xinyan Li, Ph.D | +86-13817688857 | xinyan.li@holley.cn | |
Contact: Wenyu Xu, Ph.D | +86-10-58611349 | wenyu.xu@holley.cn |
Principal Investigator: | Fengchun Zhang, Prof. | Peking Union Medical College Hospital |
Responsible Party: | Kunming Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT03396393 |
Other Study ID Numbers: |
KY41078-201 |
First Posted: | January 11, 2018 Key Record Dates |
Last Update Posted: | January 23, 2018 |
Last Verified: | January 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | This study has not been decided. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Dihydroartemisinin;Systemic Lupus Erythematosus |
Lupus Erythematosus, Systemic Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Artenimol |
Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |